All of our platforms are created by starting with a problem and identifying innovative approaches to addressing it. We are focused on the cutting edge of new science and innovation, and aim to be several years ahead of prevailing trends. View our Pipeline
Akili is building clinically validated cognitive treatments and assessments that are delivered in an action video game interface. Leveraging medical-grade science and consumer-grade software technology, Akili is seeking to produce a new type of medical product that can offer safe and effective scalable treatment and better monitoring for patients across a range of mental health and neurological conditions.
Akili's technologies are based on a proprietary neuroscience approach developed to target specific neurological systems through sensory and digital mechanics. The lead, patent-pending technology platform is based on cognitive science exclusively licensed from the lab of Dr. Adam Gazzaley at the University of California, San Francisco, and proprietary adaptive algorithms developed at Akili, all built into action video game interfaces. The platform powers both assessment and treatment products, which deploy real-time, adaptive cognitive challenges and interventions, respectively. Both products target the brain's interference processing system (an individual's core ability to process multiple streams of information), which is a key function underlying cognitive control. Akili is currently conducting multiple clinical trials of its leading digital medicine platform across a variety of patient populations, including pediatric ADHD, autism spectrum disorder (in collaboration with Autism Speaks), depression, Alzheimer’s disease and traumatic brain injury.
Gelesis is focused on the development of novel therapies to induce weight loss and improve glycemic control in people who are overweight or have obesity, including those with prediabetes and type 2 diabetes. Gelesis100, one of the company’s product candidates and a first-in-class therapeutic, is currently being evaluated in a six-month pivotal study. Gelesis is also developing Gelesis200, created from the same proprietary technology platform as Gelesis100, as a product optimized to induce weight loss and improve glycemic control in patients with type 2 diabetes.
Gelesis100 is a pivotal stage treatment for weight loss and glycemic control, which has demonstrated statistically significant weight loss and safety in its previous studies. The treatment is an orally administered capsule containing small hydrogel particles designed to employ multiple mechanisms of action along the gastrointestinal (GI) tract to induce weight loss and improve glycemic control. The hydrogel particles, which form a new chemical entity, are synthesized through Gelesis’ multi-step, proprietary process using starting materials which are considered Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration (FDA) and commonly used in the food industry.
Gelesis100 capsules are taken with water prior to a meal, after which the thousands of small hydrogel particles in each capsule are released from the capsules in the stomach and rapidly absorb water, hydrating to approximately 100 times their original size. The hydrogel particles mix homogeneously with food and travel through the GI tract, inducing weight loss and improving glycemic control. Once in the large intestine, the particles release most of the water, which is reabsorbed by the body. The microscopic degraded particles are then safely eliminated by the body in the same manner as food.
Gelesis200 leverages the proprietary hydrogel technology of Gelesis100 but has been engineered with different physical properties. It takes up slightly less volume than Gelesis100; however, it has more rapid hydration and greater elasticity and viscosity. These characteristics are designed to enhance glycemic control and weight loss for patients who have prediabetes or type 2 diabetes. Like Gelesis100, Gelesis200 is an orally administered capsule containing small hydrogel particles synthesized through Gelesis’ multi-step, proprietary process using starting materials that are considered GRAS by the FDA and commonly used in the food industry.
Vedanta Biosciences is pioneering development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, with clinical trials expected to begin in the first half of 2017. Founded by PureTech Health (PureTech Health plc, PRTC.L) and a group of world-renowned experts in immunology and microbiology, Vedanta Biosciences is a leader in the microbiome field with capabilities to discover, develop and manufacture drugs based on live bacterial consortia. Leveraging its proprietary technology platform and the expertise of its team of scientific cofounders, Vedanta Biosciences has isolated a vast collection of human-associated bacterial strains and characterized how the immune system recognizes and responds to these microbes. This work has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells and Th17 cells, among others – as well as the characterization of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science, Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulation of the microbiome has been validated by multiple randomized, controlled trials in infectious disease and inflammatory bowel disease.
Tal Medical is developing a non-invasive neuromodulation therapy for depression and other brain disorders. Tal’s proprietary Low Field Magnetic Stimulation (LFMS) technology uses a unique magnetic field waveform, with a mechanism of action different from other brain stimulation techniques such as electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS).
The previous proof-of-concept for LFMS was established at McLean Hospital in two randomized, sham-controlled studies focused primarily on bipolar depression. In those studies, a single 20-minute LFMS treatment demonstrated an immediate effect size greater than antidepressant drug treatments typically achieve in 4-10 weeks. In June of this year, Tal and Massachusetts General Hospital (MGH) reported topline data from the RAPID study of LFMS in TR-MDD, in which treatment with LFMS did not achieve the primary endpoint of HAMD6 after two 20 minute sessions in core depression symptoms compared to sham treatment, though some non-statistically significant mood improvements were detected with active LFMS on the VAS instrument.
Follica is developing a complete treatment system for hair loss, informed by scientific rigor, clinical research, and user experience design. Our approach aims not only to improve existing hair growth, but also to grow new hair. Our technology is based on a proprietary approach intended to create an "embryonic window" in adult skin, allowing new follicles and new hair to form from epithelial stem cells. This regenerative effect is called hair follicle neogenesis. Follica has an exclusive, worldwide license from the University of Pennsylvania to develop and commercialize this potentially breakthrough technology, clinically demonstrated to stimulate the genesis and development of new follicles in adult humans.
Karuna is targeting muscarinic receptors for the treatment of central nervous system (CNS) disorders. Karuna's lead program, KarXT, is a product candidate consisting of xanomeline, a novel muscarinic acetylcholine receptor agonist that has demonstrated efficacy in placebo-controlled human trials in schizophrenia and Alzheimer’s disease, and trospium chloride, an FDA-approved and well-established muscarinic receptor antagonist that has been shown not to enter the CNS.
Commense is developing novel, microbiome-derived therapeutics by priming, seeding and maintaining beneficial microbes before birth, at birth, and beyond. Decades of research support the view that microbial exposures early in life play a major role in healthy development and are believed to be very important for many conditions including diabetes, asthma, rheumatoid arthritis and Crohn’s disease. Recent work has begun to reveal the sources of these beneficial microbes, as well as strategies to optimize their transfer, colonization, and persistence in the host.
The Sync Project
Recent research has shown that music can potentially modulate neural systems like the dopamine response, autonomic nervous system and others related to stress, movement, learning and memory, suggesting that music affects the same neural pathways that are regulated by many pharmaceuticals. The Sync Project seeks to build on this foundation by creating music as personalized medicine and becoming one of the first algorithmic music therapeutics companies. The Sync Project has identified initial conditions for human pilot studies including Sleep, Pain and Athletic Performance and has begun clinical studies in the latter.
Analysis of subtle, non-linguistic changes in a person’s voice can accurately reveal important aspects about their health. Many of these changes are disease-specific and consistent across individuals, regardless of the languages they speak. Sonde leverages these findings to transform the way mental and physical health are monitored through its proprietary, voice-based technology platform. Sonde's platform is designed with the privacy of the user in mind and will work on devices most people already own.
Alivio is a novel technology for the targeted treatment of chronic and acute inflammatory disorders. Alivio is advancing its proprietary hydrogel technology, which targets inflamed tissue and delivers medication based on the levels of inflammation, potentially minimizing exposure to healthy tissue and other systemic side effects. Alivio seeks to provide a solution to the dozens of conditions where inflammation is a central part of the underlying disease pathology, but targeted and effective treatment options are lacking.
Vor is an entirely new approach to chimeric antigen receptor (CAR) T-cell therapy that has the potential to broaden its applicability and success rate in other cancers. Vor is working with some of the world’s leading oncologists and immunologists to develop a pipeline of potentially life-altering immunotherapies that extend beyond what is possible with current treatments.
Many health conditions require repeated injections of medications that are not effective when taken orally. Entrega seeks to solve the oral-delivery problem with a simple, elegant platform technology that is potentially applicable to almost any drug substance and has been demonstrated with a variety of drug molecules using in vitro and in vivo models.
resTORbio is developing a platform to address immunosenescence, an age-dependent decline in immune function. Immunosenescence is associated with a decreased ability to fight infections, an increase in cancer incidence, and a decline in organ function in the elderly. With a rapidly ageing population, there is a need to address aging-related diseases. resTORbio technology targets pathways that may revitalize immune homeostasis through inhibition of the mTOR pathway, which has been shown to extend lifespan in multiple species studied including yeast, worms, flies and mammals, and to potentially ameliorate immunosenescence in aging animals and humans.
Glyph is developing novel approaches to enhance delivery and distribution of therapeutics via the lymphatic system. The lymphatic system, often viewed as the body’s disposal system, also plays a unique role in absorbing materials from the digestive system and distributing them throughout the body, as well as modulating the body’s immune system. Unlike materials absorbed through the gut into the bloodstream, materials absorbed lymphatically bypass the portal vein and enter circulation directly, thereby avoiding first pass metabolism.
Nybo is developing monoclonal antibodies to target immuno-suppressive cells in pancreatic cancer, colorectal cancer and other solid tumors. By neutralizing immunosuppressive cells, Nybo aims to allow other immune cells to attack tumors. The overall goal is to address the great unmet medical need in malignancies with dismal prognoses that derive little benefit from current standards of care including ones that have no approved immunotherapy regimens. Nybo will leverage the translational and clinical expertise of its team of scientific co-founders and scientific advisory board members to execute its program.